FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to the use of a population of extracellular vesicles (EV) of plant origin in the therapeutic treatment of impaired angiogenesis. Use of a plant-derived population of extracellular vesicles (EVs) derived from a plant selected from the group consisting of orange, lemon, grapes, Anastatica hierochuntica (AH) and Selaginella lepidophylla (SL), wherein the extracellular vesicles (EVs) in the said population are confined to a lipid bilayer membrane and have a diameter ranging from 25 to 350 nm, and a protein content ranging from 1 to 55 ng/109 EV, in the therapeutic treatment of impaired angiogenesis.
EFFECT: above-described plant-derived vesicles used are effective for the therapeutic treatment of impaired angiogenesis.
8 cl, 19 dwg, 1 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
EXTRACELLULAR VESICLES FOR INHALATION | 2019 |
|
RU2799315C2 |
METHOD FOR TARGETED IMPACT ON EXOSOMES | 2018 |
|
RU2781640C2 |
PHARMACEUTICAL COMPOSITION COMPRISING microRNA-100 AND USE THEREOF IN MODULATING GROWTH OF BLOOD VESSELS AND ENDOTHELIUM INFLAMMATION | 2010 |
|
RU2586531C2 |
SUBSTANCES AND METHODS OF MODULATING TENDON HEALING | 2015 |
|
RU2699706C2 |
VESICLES CONTAINING PTEN INHIBITOR AND THEIR USE | 2019 |
|
RU2800729C2 |
COMPOSITIONS CONTAINING CELL VESICLES AND USE THEREOF | 2019 |
|
RU2824136C2 |
EXTRACELLULAR VESICLES ORIGINATING FROM MESENCHYMAL STEM CELLS | 2019 |
|
RU2805066C2 |
METHOD FOR ACUTE KIDNEY DAMAGE DIAGNOSTICS AND/OR PREDICTION | 2010 |
|
RU2629591C2 |
METHODS FOR PATHOLOGICAL CHANGES DETECTION IN ORGAN OR SYSTEM OF ORGANS | 2012 |
|
RU2626540C2 |
METHODS OF TREATING POLYCYSTIC KIDNEY DISEASE | 2016 |
|
RU2742300C2 |
Authors
Dates
2024-01-30—Published
2020-03-12—Filed